Estradiol Valerate
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Estradiol Valerate
- Estradiol Valerate: From Estrogen Therapy to Symptomatic Fragile X Syndrome in Female Carriers
Estradiol Valerate: From Estrogen Therapy to Symptomatic Fragile X Syndrome in Female Carriers
One-Sentence Summary
Estradiol valerate is an injectable estrogen ester, marketed in the United States under one brand-name NDA (Delestrogen) and generic ANDAs. The TxGNN model predicts it may be useful for the symptomatic form of fragile X syndrome in female carriers. Currently 0 clinical trials and 0 publications support this specific prediction, so it rests on the model score alone.
Quick Overview
| Item | Content |
|---|---|
| Predicted New Indication | Symptomatic form of fragile X syndrome in female carrier |
| TxGNN Prediction Score | 99.94% |
| Evidence Level | L5 (model prediction only) |
| US Market Status | ✓ Marketed |
| Number of NDAs | 10 license records (3 unique numbers among the 5 listed) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Estradiol valerate is an estrogen ester, and estrogen replacement is an established supportive treatment for low estrogen states. Its efficacy in its labeled uses is presumed, but the source data does not list an approved indication.
The most plausible link is indirect. Women who carry a fragile X premutation can develop fragile X-associated primary ovarian insufficiency (FXPOI), and estrogen replacement is standard supportive care for the resulting hypoestrogenism. That would be a symptom-level overlap with existing estrogen use.
It would not be evidence that estradiol valerate benefits fragile X syndrome itself. The model score is very high (99.94%), but without trials or literature it should be treated as a hypothesis only.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| NDA009402 | Delestrogen (Par Health USA, LLC) | Injection | Not listed in source data |
| ANDA203723 | Estradiol Valerate (Hikma Pharmaceuticals USA Inc.) | Injection | Not listed in source data |
| ANDA216656 | Estradiol valerate (Xiromed, LLC) | Injection | Not listed in source data |
The source records show 10 licenses in total. Only 5 records were provided, and two of them repeat the same ANDA numbers, so 3 unique authorizations are shown above.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has no supporting clinical trials or literature (L5). The only plausible mechanism is treating FXPOI-related estrogen deficiency, not fragile X syndrome itself.
Of the ten predictions in the Evidence Pack, “ovarian dysfunction” (rank 10) is the most biologically coherent. It is likely on-label or overlapping with existing estrogen use, so it is not a true repurposing. Estradiol valerate also induces cystic ovarian changes in rodent models, so any benefit depends on whether the context is estrogen deficiency or a PCOS-type disorder.
To proceed, the following is needed:
- Package insert warnings and contraindications, which are currently missing and block safety screening
- Approved indication text and mechanism of action data
- A targeted literature and trial search on estrogen replacement in FXPOI and fragile X premutation carriers
- Clinical input on whether FXPOI management counts as a distinct new indication or falls within existing estrogen use
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.